MARKET

VRDN

VRDN

Viridian Therapeutics Inc
NASDAQ
12.39
-0.39
-3.05%
After Hours: 12.36 -0.03 -0.24% 16:24 05/09 EDT
OPEN
12.76
PREV CLOSE
12.78
HIGH
13.13
LOW
12.36
VOLUME
655.73K
TURNOVER
--
52 WEEK HIGH
27.20
52 WEEK LOW
9.90
MARKET CAP
1.01B
P/E (TTM)
-2.9252
1D
5D
1M
3M
1Y
5Y
1D
Viridian Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating
TipRanks · 2d ago
What 5 Analyst Ratings Have To Say About Viridian Therapeutics
Benzinga · 3d ago
Viridian Therapeutics receives FDA breakthrough designation for Veligrotug
TipRanks · 3d ago
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation For Veligrotug For Thyroid Eye Disease
Benzinga · 3d ago
VIRIDIAN THERAPEUTICS- VELIGROTUG MET ALL PRIMARY AND SECONDARY ENDPOINTS IN PIVOTAL THRIVE AND THRIVE-2 CLINICAL TRIALS IN ACTIVE AND CHRONIC TED
Reuters · 3d ago
VIRIDIAN THERAPEUTICS- BLA SUBMISSION FOR VELIGROTUG ON TRACK FOR SECOND HALF 2025 WITH A PLANNED U.S. LAUNCH IN 2026, IF APPROVED
Reuters · 3d ago
Viridian Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 3d ago
Viridian Therapeutics Price Target Cut to $45.00/Share From $46.00 by RBC Capital
Dow Jones · 3d ago
More
About VRDN
More
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Recently
Symbol
Price
%Change

Webull offers Viridian Therapeutics Inc stock information, including NASDAQ: VRDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRDN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRDN stock methods without spending real money on the virtual paper trading platform.